Mitochondrial abnormalities-A link to idiosyncratic drug hepatotoxicity?

Toxicology and Applied Pharmacology

Volumn 220, Issue 1, 2007, Pages 92-107

  Boelsterli, Urs A ^a,b   Lim, Priscilla L K ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Drug idiosyncrasy; Drug induced liver injury; Mitochondria; Oxidative stress; Susceptibility factors

Indexed keywords

AMIODARONE; DANTROLENE; DICLOFENAC; FIALURIDINE; ISONIAZID; LAMIVUDINE; LEFLUNOMIDE; MEFENAMIC ACID; NIMESULIDE; SIMVASTATIN; STAVUDINE; SULINDAC; TOLCAPONE; TROGLITAZONE; TROVAFLOXACIN; VALPROIC ACID;

CELL DEATH; DISEASE PREDISPOSITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; ENZYME POLYMORPHISM; HETEROPLASMY; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; INFLAMMATION; LIVER TOXICITY; MITOCHONDRIAL MEMBRANE; NONHUMAN; PROTEIN DEFECT; REVIEW;

ANIMALS; DNA, MITOCHONDRIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INCIDENCE; LIVER DISEASES; MITOCHONDRIA; MITOCHONDRIAL DISEASES; PHARMACEUTICAL PREPARATIONS;

ANIMALIA;

EID: 33947204690     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.12.013     Document Type: Review

References (152)

1. Amacher D.E. Drug-associated mitochondrial toxicity and its detection. Curr. Med. Chem. 12 (2005) 1829-1839
2. Amuzie C.J., Li M., Ganey P.A., Roth R.A., Cuff C.F., and Pestka J.P. Reovirus exposure potentiates acetaminophen hepatotoxicity. Toxicol. Sci. 90 (2006) 204 (supplement)
3. Armstrong J.S. The role of the mitochondrial permeability transition in cell death. Mitochondrion 6 (2006) 225-234
4. Atarod E.B., and Kehrer J.P. Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines. Free Radic. Biol. Med. 37 (2004) 36-47
5. Barreiro E., Coronell C., Lavina B., Ramirez-Sarmiento A., Orozco-Levi M., and Gea J. Aging, sex differences, and oxidative stress in human respiratory and limb muscles. Free Radic. Biol. Med. 41 (2006) 797-809
6. y mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J. Hepatol. 35 (2001) 17-23
7. Berson A., DeBeco V., Lettéron P., Robin M.A., Moreau C., ElKahwaji J., Verthier N., Feldmann G., Fromenty B., and Pessayre D. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114 (1998) 764-774
8. Bjorge S.M., and Baillie T.A. Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations. Drug Metab. Dispos. 19 (1991) 823-829
9. Blattner J.R., He L., and Lemasters J.J. Screening assays for the mitochondrial permeability transition using a fluorescence multiwell plate reader. Anal. Biochem. 295 (2001) 220-226
10. Boelsterli U.A. Idiosyncratic drug hepatotoxicity revisited: new insights from mechanistic toxicology. Toxicol. Mech. Methods 13 (2003) 3-20
11. Bort R., Ponsoda X., Jover R., Gomez-Lechon M.J., and Castell J.V. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J. Pharmacol. Exp. Ther. 288 (1998) 65-72
12. Bova M.P., Tam D., McMahon G., and Mattson M.N. Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol. Lett. 155 (2005) 41-50
13. Buchweitz J.P., Ganey P.E., Bursian S.J., and Roth R.A. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?. J. Pharmacol. Exp. Ther. 300 (2002) 460-467
14. Cafforio P., Dammacco F., Gernone A., and Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26 (2005) 883-891
15. Caparroz-Assef S.M., Salgueiro-Pagadigorria C.L., Bersani-Amado C.A., Bracht A., Kelmer-Bracht A.M., and Ishii-Iwamoto E.L. The uncoupling effect of the nonsteroidal anti-inflammatory drug nimesulide in liver mitochondria from adjuvant-induced arthritic rats. Cell Biochem. Funct. 19 (2001) 117-124
16. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev., Drug Discov. 2 (2003) 624-634
17. Chinnery P.F., Johnson M.A., Wardell T.M., Singh-Kler R., Hayes C., Brown D.T., Taylor R.W., Bindoff L.A., and Turnbull D.M. The epidemiology of pathogenic mitochondrial DNA mutations. Ann. Neurol. 48 (2000) 188-193
18. Chowdhury A., Santra A., Bhattacharjee K., Ghatak S., Saha D.R., and Dhali G.K. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J. Hepatol. 45 (2006) 117-126
19. Coon K.D., Valla J., Szelinger S., Schneider L.E., Niedzielko T.L., Brown K.M., Pearson J.V., Halperin R., Dunckley T., Papassotiropoulos A., Caselli R.J., Reiman E.M., and Stephan D.A. Quantitation of heteroplasmy of mtDNA sequence variants identified in a population of AD patients and controls by array-based resequencing. Mitochondrion 6 (2006) 194-210
20. Cortopassi G., and Wang E. Modelling the effects of age-related mtDNA mutation accumulation: complex I deficiency, superoxide and cell death. Biochim. Biophys. Acta 1271 (1995) 171-176
21. Daouphars M., Koufany M., Benani A., Marchal S., Merlin J.L., Netter P., and Jouzeau J.Y. Uncoupling of oxidative phosphorylation and Smac/DIABLO release are not sufficient to account for induction of apoptosis by sulindac sulfide in human colorectal cancer cells. Int. J. Oncol. 26 (2005) 1069-1077
22. Darios F., Lambeng N., Troadec J.D., Michel P.P., and Ruberg M. Ceramide increases mitochondrial free calcium levels via caspase 8 and Bid: role in initiation of cell death. J. Neurochem. 84 (2003) 643-654
23. Davis R.E., Miller S., Herrnstadt C., Ghosh S.S., Fahy E., Shinobu L.A., Galasko D., Thal L.J., Beal M.F., Howell N., and Parker W.D. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 4526-4531
24. Deng X., Stachlewitz R.F., Liguori M.J., Blomme E.A., Waring J.F., Luyendyk J.P., Maddox J.F., Ganey P.A., and Roth R.A. Modest inflammation enhances diclofenac hepatotoxicity in rats: a potential animal model for idiosyncratic drug reaction. Toxicol. Sci. 90 (2006) 350-351 (supplement)
25. Deschamps D., DeBeco V., Fisch C., Fromenty B., Guillouzo A., and Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 19 (1994) 948-961
26. Dias N., and Bailly C. Drugs targeting mitochondrial functions to control tumor cell growth. Biochem. Pharmacol. 70 (2005) 1-12
27. DiMauro S., and Schon E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 348 (2003) 2656-2668
28. Divi R.L., Leonard S.L., Kuo M.M., Walker B.L., Orozco C.C., St. Claire M.C., Nagashima K., Harbaugh S.W., Harbaugh J.W., Thamire C., Sable C.A., and Poirier M.C. Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors. Cardiovasc. Toxicol. 5 (2005) 333-346
29. Divi, R.L., Leonard, S.L., Kuo, M.M., Nagashima, K., Thamire, C., St. Claire, M.C., Wade, N.A., Walker, V.E., Poirier, M.C. in press. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ. Mol. Mutagen.
30. Eaton D.L., and Klaassen C.D. Principles of toxicology. In: Klaassen C.D. (Ed). Casarett and Doull's Toxicology. The Basic Science of Poisons. 5th ed. (1996), McGraw-Hill, New York, N.Y. 13-33
31. Evans D.C., Watt A.P., Nicoll-Griffith D.A., and Baillie T.A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17 (2004) 3-16
32. Feng J.Y., Johnson A.A., Johnson K.A., and Anderson K.S. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J. Biol. Chem. 276 (2001) 23832-23837
33. Fromenty B., Fisch C., Labbe G., Degott C., Deschamps D., Berson A., Lettéron P., and Pessayre D. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric incoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J. Pharmacol. Exp. Ther. 255 (1990) 1377-1384
34. Fromenty B., Letteron P., Fisch C., Berson A., Deschamps D., and Pessayre D. Evaluation of human blood lymphocytes as a model to study the effects of drugs on human mitochondria. Effects of low concentrations of amiodarone on fatty acid oxidation, ATP levels and cell survival. Biochem. Pharmacol. 46 (1993) 421-432
35. Gaou I., Malliti M., Guimont M.C., Letteron P., Demeilliers C., Peytavin G., Degott C., Pessayre D., and Fromenty B. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J. Pharmacol. Exp. Ther. 297 (2001) 516-523
36. Gerschenson M., Nguyen V.T., St. Claire M.C., Harbaugh S.W., Harbaugh J.W., Proia L.A., and Poirier M.C. Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys. J. Hum. Virol. 4 (2001) 335-342
37. Gomez-Lechon M.J., Ponsoda X., O'Connor E., Donato T., and Castell J.V. Diclofenac induces apoptosis in hepatocytes. Toxicol. In Vitro 17 (2003) 675-680
38. Gomez-Lechon M.J., Ponsoda X., O'Connor E., Donato T., Castell J.V., and Jover R. Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS. Biochem. Pharmacol. 66 (2003) 2155-2167
39. Gunawan B., Liu Z.X., Han D., Hanawa N., Gaarde W.A., and Kaplowitz N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 131 (2006) 165-178
40. Guo L.J., Oshida Y., Fuku N., Takeyasu T., Fujita Y., Kurata M., Sato Y., Ito M., and Tanaka M. Mitochondrial genome polymorphisms associated with type-2 diabetes or obesity. Mitochondrion 5 (2005) 15-33
41. Haasio K., Koponen A., Penttilä K.E., and Nissinen E. Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol. 453 (2002) 21-26
42. Haasio K., Lounatmaa K., and Sukura A. Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo. Exp. Toxicol. Pathol. 54 (2002) 9-14
43. Haasio K., Nissinen E., Sopanen L., and Heinonen E.H. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. J. Neural Transm. 109 (2002) 1391-1401
44. Haskins J.R., Rowse P., Rahbari R., and de la Iglesia F.A. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch. Toxicol. 75 (2001) 425-438
45. Holohan P.D., LaRocca D., and Lehmann D.F. A novel explanation of idiosyncratic drug toxicity. Drug Metab. Rev. 36 Suppl. 1 (2004) 232
46. Horn D.M., Neeb L.A., Colacino J.M., and Richardson F.C. Fialuridine is phosphorylated and inhibits DNA synthesis in isolated rat hepatic mitochondria. Antivir. Res. 34 (1997) 71-74
47. Huang T.T., Carlson E.J., Raineri I., Gillespie A.M., Kozy H., and Epstein C.J. The use of transgenic and mutant mice to study oxygen free radical metabolism. Ann. N.Y. Acad. Sci. 893 (1999) 95-112
48. Inoue A., Muranaka S., Fujita H., Kanno T., Tamai H., and Utsumi K. Molecular mechanisms of diclofenac-induced apoptosis of promyelocytic leukemia: dependency on reactive oxygen species, Akt, Bid, cytochrome c, and caspase pathway. Free Radic. Biol. Med. 37 (2004) 1290-1299
49. Iwase M., Yamaguchi M., Yoshinari M., Okamura C., Hirahashi T., Tsuji H., and Fujishima M. A Japanese case of liver dysfunction after 19 months of troglitazone treatment. Diabetes Care 22 (1999) 1382
50. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4 (2005) 489-499
51. Kass G.E.N. Mitochondrial involvement in drug-induced hepatic injury. Chem.-Biol. Interact. 163 (2006) 145-159
52. Kaufmann P., Torok M., Hanni A., Roberts P., Gasser R., and Krähenbühl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 41 (2005) 925-935
53. Kawagoe R., Kawagoe H., and Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk. Res. 26 (2002) 495-502
54. Keller B.J., Yamanaka H., and Thurman R.G. Inhibition of mitochondrial respiration and oxygen-dependent hepatotoxicity by six structurally dissimilar peroxisomal proliferating agents. Toxicology 71 (1992) 49-61
55. +/- mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 2278-2283
56. Konrad D., Rudich A., Bilan P.J., Patel N., Richardson C., Witters L.A., and Klip A. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 48 (2005) 954-966
57. Korlipara L.V.P., Cooper J.M., and Schapira A.H.V. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacol. 46 (2004) 562-569
58. Krähenbühl S., Brandner S., Kleinle S., Liechti S., and Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 20 (2000) 346-348
59. Krause M.M., Brand M.D., Krauss S., Meisel C., Vergin H., Burmester G.R., and Buttgereit F. Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. Arthritis Rheum. 48 (2003) 1438-1444
60. Kujoth G.C., Hiona A., Pugh T.D., Someya S., Panzer K., Wohlgemuth S.E., Hofer T., Seo A.Y., Sullivan R., Jobling W.A., Morrow J.D., Van Remmen H., Sedivy J.M., Yamasoba T., Tanokura M., Weindruch R., Leeuwenburgh C., and Prolla T.A. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309 (2005) 481-484
61. Latchoumycandane C., Seah Q.M., Tan R.C.H., Sattabongkot J., Beerheide W., and Boelsterli U.A. Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes. Toxicol. Appl. Pharmacol. 217 (2006) 125-133
62. Lebovitz R.M., Zhang H., Vogel H., Cartwright J., Dionne L., Lu N., Huang S., and Matzuk M.M. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9782-9787
63. Leeder J.S. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 39 Suppl. 7 (1998) S8-S16
64. Leite S., Martins N.M., Dorta D.J., Curti C., Uyemura S.A., and dos Santos A.C. Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide. Basic Clin. Pharmacol. Toxicol. 99 (2006) 294-299
65. Leitner H., and Day B. Mitochondrial antioxidant status and nucleoside reverse transcriptase inhibitor (NRTI) associated toxicity. Toxicol. Sci. 90 (2006) 351 (abstract, suppl.)
66. Lewis W., and Dalakas M.C. Mitochondrial toxicity of antiviral drugs. Nat. Med. 1 (1995) 411-417
67. Lewis W., Griniuviene B., Tankersley K.O., Levine E.S., Montione R., Engelman L., de Courten-Myers G., Ascenzi M.A., Hornbuckle W.E., Gerin J.L., and Tennant B.C. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab. Invest. 76 (1997) 77-87
68. Lewis W., Copeland W.C., and Day B. Mitochondrial DNA depletion, oxidative stress and mutation: mechanisms of nucleoside reverse transcriptase inhibitor toxicity. Lab. Invest. 81 (2001) 777-790
69. Lewis W., Day B.J., and Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2 (2003) 812-822
70. Li A.P. A review of the common properties of drugs with idiosyncratic hepatotoxicity and "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem.-Biol. Interact. 142 (2002) 7-23
71. Liguori M.J., Anderson M.G., Bukofzer S., McKim J., Pregenzer J.F., Retief J., Spear B.B., and Waring J.F. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 41 (2005) 177-186
72. Lim M.S., Lim P.L.K., Gupta R., and Boelsterli U.A. Critical role of free cytosolic calcium, but not uncoupling, in mitochondrial permeability transition and cell death induced by diclofenac oxidative metabolites in immortalized human hepatocytes. Toxicol. Appl. Pharmacol. 217 (2006) 322-331
73. Liu Z.X., Govindarajan S., and Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 127 (2004) 1760-1774
74. Lopez S., Miro O., Martinez E., Pedrol E., Rodriguez-Santiago B., Milinkovic A., Soler A., Garcia-Viejo M.A., Nunes V., Casademont J., Gatell J.M., and Cardellach F. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir. Ther. 9 (2004) 47-55
75. Luyendyk J.P., Maddox J.F., Cosma G.N., Ganey P.A., Cockerell G.L., and Roth R.A. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 307 (2003) 9-16
76. Maddox J.F., Luyendyk J.P., Cosma G.N., Breau A.P., Bible R.H., Harrigan G.G., Goodacre R., Ganey P.A., Cantor G.H., Cockerell G.L., and Roth R.A. Metabonomic evaluation of idiosyncrasy-like liver injury in rats cotreated with ranitidine and lipopolysaccharide. Toxicol. Appl. Pharmacol. 212 (2006) 35-44
77. Majamaa K., Moilanen J.S., Uimonen S., Remes A.M., Salmela P.I., Karppa M., Majamaa-Voltti K.A.M., Rusanen H., Sorri M., Peuhkurinen K.J., and Hassinen I.E. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence, of the mutation in an adult population. Am. J. Hum. Genet. 63 (1998) 447-454
78. Masubuchi Y., Saito H., and Horie T. Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes. J. Pharmacol. Exp. Ther. 287 (1998) 208-213
79. Masubuchi Y., Yamada S., and Horie T. Diphenylamine as an important structure of nonsteroidal anti-inflammatory drugs to uncouple mitochondrial oxidative phosphorylation. Biochem. Pharmacol. 58 (1999) 861-865
80. Masubuchi Y., Yamada S., and Horie T. Possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 292 (2000) 982-987
81. Masubuchi Y., Nakayama S., and Horie T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35 (2002) 544-551
82. Masubuchi Y., Kano S., and Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicoloy 222 (2006) 233-239
83. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
84. McDougall P., Markham A., Cameron I., and Sweetman A.J. The mechanism of inhibition of mitochondrial oxidative phosphorylation by the non-steroidal anti-inflammatory agent diflunisal. Biochem. Pharmacol. 32 (1983) 2595-2598
85. McKenzie R., Fried M.W., Sallie R., Conjeevaram H., Di Bisceglie A.M., Park Y., Savarese B., Kleiner D., Tsokos M., Luciano C., Pruett T., Stotka J.L., Straus S.E., and Hoofnagle J.H. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 26 (1995) 1099-1105
86. Melegh B., and Trombitas K. Valproate treatment induces lipid globule accumulation with ultrastructural abnormalities of mitochondria in skeletal muscle. Neuropediatrics 28 (1997) 257-261
87. Mingatto F.E., Santos A.C., Uyemura S.A., Jordani M.C., and Curti C. In vitro interaction of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: respiration and ATP synthesis. Arch. Biochem. Biophys. 334 (1996) 303-308
88. Mingatto F.E., Cardozo dos Santos A., Rodrigues T., Pigoso A.A., Uyemura S.A., and Curti C. Effects of nimesulide and its reduced metabolite on mitochondria. Br. J. Pharmacol. 131 (2000) 1154-1160
89. Mingatto, F.E., Rodrigues, T., Pigoso, A.A., Uyemura, S.A., Curti, C.M., Santos, A.C., 2002. The critical role of mitochondrial energetic impairment in the toxicity of nimesulide to hepatocytes. J. Pharmacol. Exp. Ther. 303, 601-607.
90. Moreno-Sanchez R., Bravo C., Vasquez C., Ayala G., Silveira L.H., and Martinez-Lavin M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs. Biochem. Pharmacol. 57 (1999) 743-752
91. Munns S.E., Lui J.K., and Arthur P.G. Mitochondrial hydrogen peroxide production alters oxygen consumption in an oxygen-dependent manner. Free Radic. Biol. Med. 38 (2005) 1594-1603
92. Narayanan P.K., Hart T., Elcock F., Zhang C., Hahn L., McFarland D., Schwartz L., Morgan D.G., and Bugelski P. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. Cytometry, Part A 52A (2003) 28-35
93. Navarro V.J., and Senior J.R. Drug-related hepatotoxicity. N. Engl. J. Med. 354 (2006) 731-739
94. Nebert D.W. Inter-individual susceptibility to environmental toxicants-a current assessment. Toxicol. Appl. Pharmacol. 207 (2005) S34-S42
95. Note R., Maisonneuve C., Letteron P., Peytavin G., Djouadi F., Igoudjil A., Guimont M.C., Biour M., Pessayre D., and Fromenty B. Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single-and three dual-NRTI treatments. Antimicrob. Agents Chemother. 47 (2003) 3384-3392
96. Oliveira P.J., and Wallace K.B. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats-relevance for mitochondrial dysfunction. Toxicology 220 (2006) 160-168
97. +/- mice. Free Radic. Biol. Med. 40 (2006) 420-429
98. Ong, M.M.K., Latchoumycandane, C., and Boelsterli, U.A., in press. Troglitazone-induced hepatic necrosis in an animal model of silent mitochondrial abnormalities. Toxicol. Sci.
99. Pace C.S., Martin A.M., Hammon E.L., Mamotte C.D., Nolan D.A., and Mallal S.A. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir. Ther. 8 (2003) 323-331
100. Park B.K., Kitteringham N.R., Powell H., and Pirmohamed M. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 153 (2000) 39-60
101. Park Y.C., Jeong J.H., Park K.J., Choi H.J., Park Y.M., Jeong B.K., Higuchi Y., and Yoo Y.H. Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells. Life Sci. 77 (2005) 2059-2070
102. Persky A.M., Green P.S., Stubley L., Howell C.O., Zaulyanov L., Brazeau G.A., and Simpkins J.W. Protective effect of estrogens against oxidative damage to heart and skeletal muscle in vivo and in vitro. Proc. Soc. Exp. Biol. Med. 223 (2000) 59-66
103. Pessayre D., Fromenty B., Mansouri A., and Berson A. Hepatotoxicity due to mitochondrial injury. In: Kaplowitz N., and DeLeve L. (Eds). Drug-Induced Liver Disease (2003), Marcel Dekker Inc., New York, NY 55-83
104. Petersen K.F., Befroy D., Dufour S., Dziura J., Ariyan C., Rothman D.L., DiPietro L., Cline G.W., and Shulman G.I. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300 (2003) 1140-1142
105. Petrescu I., and Tarba C. Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. Biochim. Biophys. Acta (Bioenergetics) 1318 (1997) 385-394
106. Pigoso A.A., Uyemura S.A., Santos A.C., Rodrigues T., Mingatto F.E., and Curti C. Influence of nonsteroidal anti-inflammatory drugs on calcium efflux in isolated rat renal cortex mitochondria and aspects of the mechanisms involved. Int. J. Biochem. Cell Biol. 30 (1998) 961-965
107. Pinkert C.A., and Trounce I.A. Animal modeling: from transgenics to transmitochondrial models. In: Berdanier C.D. (Ed). Mitochondria in Health and Disease (2005), Taylor and Francis, Boca Raton, FL 559-580
108. Pirmohamed M., and Park B.K. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22 (2001) 298-305
109. Ponchaut S., van Hoof F., and Veitch K. Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration. Biochem. Pharmacol. 43 (1992) 644-647
110. Pulkes T., and Hanna M.G. Human mitochondrial DNA diseases. Adv. Drug Deliv. Rev. 49 (2001) 27-43
111. Rolo A.P., and Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol. 212 (2006) 167-178
112. Roth R.A., Harkema J.R., Pestka J.P., and Ganey P.E. Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents?. Toxicol. Appl. Pharmacol. 147 (1997) 300-311
113. Roth R.A., Luyendyk J.P., Maddox J.F., and Ganey P.A. Inflammation and drug idiosyncrasy-is there a connection?. J. Pharmacol. Exp. Ther. 307 (2003) 1-8
114. Schon E.A. Mitochondrial genetics and disease. Trends Biochem. Sci. 25 (2000) 555-560
115. Schwab C.E., and Tuschl H. In vitro studies on the toxicity of isoniazid in different cell lines. Hum. Exp. Toxicol. 22 (2003) 607-615
116. Semino-Mora C., Leon-Monzon M., and Dalakas M.C. Mitochondrial and cellular toxicity induced by fialuridine in human muscle in vitro. Lab. Invest. 76 (1997) 487-495
117. Sgro C., Clinard F., Ouazir K., Chanay H., Allard C., Guilleminet C., Lenoir C., Lemoine A., and Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36 (2002) 451-455
118. Shanske S., and Wong L.J.C. Molecular analysis for mitochondrial DNA disorders. Mitochondrion 4 (2004) 403-415
119. Shenton J.M., Chen J., and Uetrecht J. Animal models of idiosyncratic drug reactions. Chem.-Biol. Interact. 150 (2004) 53-70
120. Shishido S., Koga H., Harada M., Kumemura H., Hanada S., Taniguchi E., Kumashiro R., Ohira H., Sato Y., Namba M., Ueno T., and Sata M. Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37 (2003) 136-147
121. Shoffner J.M. Maternal inheritance and the evaluation of oxidative phosphorylation diseases. Lancet 348 (1996) 1283-1288
122. Sinicrope F.A., and Penington R.C. Sulindac sulfide-induced apoptosis is enhanced by a small molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol. Cancer Ther. 4 (2005) 1475-1483
123. Sobaniec-Lotowska M.E. Effects of long-term administration of the antiepileptic drug sodium valproate upon the ultrastructure of hepatocytes in rats. Exp. Toxicol. Pathol. 49 (1997) 225-232
124. Spahr L., Rubbia-Brandt L., Burkhard P.R., Assal F., and Hadengue A. Tolcapone-related fulminant hepatitis. Dig. Dis. Sci. 45 (2000) 1881-1884
125. Spaniol M., Bracher R., Ha H.R., Follath F., and Krähenbühl S. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J. Hepatol. 35 (2001) 628-636
126. Spodnik J.H., Wozniak M., Budzko D., Teranishi M.A., Karbowski M., Nishizawa Y., Usukara J., and Wakabayashi T. Mechanism of leflunomide-induced proliferation of mitochondria in mammalian cells. Mitochondrion 2 (2002) 163-179
127. Strehlow K., Rotter S., Wassmann S., Adam O., Grohe C., Laufs K., Bohm M., and Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. Circ. Res. 25 (2003) 170-177
128. Suzuki S., Hinokio Y., Komatu K., Ohtomo M., Onoda M., Hirai S., Hirai M., Hirai A., Chiba M., Kasuga S., Akai H., and Toyota T. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res. Clin. Pract. 45 (1999) 161-168
129. Tafazoli S., Spehar D.D., and O'Brian P.J. Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab. Rev. 37 (2005) 311-325
130. Taib N.T., Jarrar B.M., and Mubarak M.M. Ultrastructural alterations in renal tissues of rabbits induced by diclofenac sodium (Voltaren). Saudi Med. J. 25 (2004) 1360-1365
131. Tang W., Borel A.G., Fujimiya T., and Abbott F.S. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol. 8 (1995) 671-682
132. Tay V.K.S., Wang A.S., Leow K.Y., Ong M.M.K., Wong K.P., and Boelsterli U.A. Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic. Biol. Med. 39 (2005) 949-959
133. Taylor R.W., and Turnbull D.M. Mitochondrial DNA mutations in human disease. Nat. Rev., Genet. 6 (2005) 389-402
134. Tirmenstein M.A., Hu C.X., Gales T.L., Maleeff B.E., Narayanam P.K., Kurali E., Hart T.K., Thomas H.C., and Schwartz L.W. Effect of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 69 (2002) 131-138
135. Tong V., Teng X.W., Chang T.K.H., and Abbott F.S. Valproic acid: II. Effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol. Sci. 86 (2005) 436-443
136. Trost L.C., and Lemasters J.J. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J. Pharmacol. Exp. Ther. 278 (1996) 1000-1005
137. Uetrecht J.P. New concepts in immunology relevant to idiosyncratic drug reactions: the "Danger Hypothesis" and innate immune system. Chem. Res. Toxicol. 12 (1999) 387-395
138. Uetrecht J.P. Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions?. Curr. Drug Metab. 1 (2000) 133-141
139. Uyemura S.A., Santos A.C., Mingatto F.E., Jordani M.C., and Curti C. Diclofenac sodium and mefenamic acid: potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch. Biochem. Biophys. 342 (1997) 231-235
140. Van Remmen H., Salvador C., Yang H., Huang T.T., Epstein C.J., and Richardson A. Characterization of the antioxidant status of the heterozygous manganese superoxide dismutase knockout mouse. Arch. Biochem. Biophys. 363 (1999) 91-97
141. Van Remmen H., Ikeno Y., Hamilton M., Pahlavani M., Wolf N., Thorpe S.R., Alderson N.L., Baynes J.W., Epstein C.J., Huang T.T., Nelson J., Strong R., and Richardson A. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol. Genomics 16 (2003) 29-37
142. Varbiro G., Toth A., Tapodi A., Bognar Z., Veres B., Sumegi B., and Gallyas F. Protective effects of amiodarone but not N-desethylamiodarone on postischemic hearts through the inhibition of mitochondrial permeability transition. J. Pharmacol. Exp. Ther. 307 (2003) 615-625
143. Velho J.A., Okanobo H., Degasperi G.R., Matsumoto M.Y., Alberici L.C., Cosso R.G., Oliveria H.C., and Vercesi A.E. Statins induce calcium-dependent mitochondrial permeability transition. Toxicology 219 (2006) 124-132
144. Velsor L.W., Kovacevic M., Goldstein M., Leitner H.M., Lewis W., and Day B.J. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol. Appl. Pharmacol. 199 (2004) 10-19
145. Wallace K.B., and Starkov A.A. Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 353-388
146. Wang E., and Cortopassi G. Mice with duplications and deletions at the Tme locus have altered MnSOD activity. J. Biol. Chem. 269 (1994) 22463-22465
147. Waring J.F., Liguori M.J., Luyendyk J.P., Maddox J.F., Ganey P.A., Stachlewitz R.F., North C., Blomme E.A., and Roth R.A. LPS cotreated rats as a model for trovafloxacin-induced idiosyncratic hepatotoxicity. Toxicol. Sci. 90 supplement (2006) 350
148. Watanabe I., Tomita A., Shimizu M., Sugawara M., Yasumo H., Koishi R., Takahashi T., Miyoshi K., Nakamura K., Izumi T., Matsushita Y., Furukawa H., Haruyama H., and Koga T. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 73 (2003) 435-455
149. Watkins P.B., and Seeff L.B. Drug-induced live injury: summary of a single topic clinical research conference. Hepatology 43 (2006) 618-631
150. Westwood F.R., Bigley A., Randall K., Marsden A.M., and Scott R.C. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol. Pathol. 33 (2005) 246-257
151. Williams D.P., and Park B.K. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Disc. Today 8 (2003) 1044-1050
152. Williams M.D., Van Remmen H., Conrad C.C., Huang T.T., Epstein C.J., and Richardson A. Increased oxidative damage is correlated to mitochondrial function in heterozygous manganese dismutase knockout mice. J. Biol. Chem. 273 (1998) 28510-28515